JP2025504363A - γδT細胞結合ポリペプチド及びその使用 - Google Patents

γδT細胞結合ポリペプチド及びその使用 Download PDF

Info

Publication number
JP2025504363A
JP2025504363A JP2024540715A JP2024540715A JP2025504363A JP 2025504363 A JP2025504363 A JP 2025504363A JP 2024540715 A JP2024540715 A JP 2024540715A JP 2024540715 A JP2024540715 A JP 2024540715A JP 2025504363 A JP2025504363 A JP 2025504363A
Authority
JP
Japan
Prior art keywords
seq
cancer
polypeptide
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504363A5 (cg-RX-API-DMAC7.html
Inventor
ブライアン アール. ベックランド
カイル エス. ジョーンズ
ケイトリン エヌ. ロビンソン
アンドルー エム. エクルズ
ジョン シー. ティマー
ブレンダン ピー. エッケルマン
Original Assignee
インヒブルクス バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インヒブルクス バイオサイエンシズ インコーポレイテッド filed Critical インヒブルクス バイオサイエンシズ インコーポレイテッド
Publication of JP2025504363A publication Critical patent/JP2025504363A/ja
Publication of JP2025504363A5 publication Critical patent/JP2025504363A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024540715A 2022-01-05 2023-01-04 γδT細胞結合ポリペプチド及びその使用 Pending JP2025504363A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296774P 2022-01-05 2022-01-05
US63/296,774 2022-01-05
US202263417926P 2022-10-20 2022-10-20
US63/417,926 2022-10-20
PCT/US2023/060074 WO2023133394A1 (en) 2022-01-05 2023-01-04 Gamma delta t-cell-binding polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
JP2025504363A true JP2025504363A (ja) 2025-02-12
JP2025504363A5 JP2025504363A5 (cg-RX-API-DMAC7.html) 2025-12-26

Family

ID=85199216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540715A Pending JP2025504363A (ja) 2022-01-05 2023-01-04 γδT細胞結合ポリペプチド及びその使用

Country Status (11)

Country Link
US (1) US20250066477A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460521A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025504363A (cg-RX-API-DMAC7.html)
KR (1) KR20240130130A (cg-RX-API-DMAC7.html)
CN (1) CN119213028A (cg-RX-API-DMAC7.html)
AU (1) AU2023205911A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242658A1 (cg-RX-API-DMAC7.html)
IL (1) IL314073A (cg-RX-API-DMAC7.html)
MX (1) MX2024008389A (cg-RX-API-DMAC7.html)
TW (1) TW202334233A (cg-RX-API-DMAC7.html)
WO (1) WO2023133394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140683A1 (zh) * 2023-12-29 2025-07-03 北京鼎成肽源生物技术有限公司 表达趋化因子10和白介素15的工程化免疫细胞
WO2025144974A1 (en) * 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2026006719A1 (en) * 2024-06-28 2026-01-02 IN8bio, Inc. Multifunctional molecules and methods of treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトVγ9Vδ2 T細胞受容体と結合する免疫グロブリン
WO2020159368A1 (en) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
WO2021113558A2 (en) * 2019-12-03 2021-06-10 Adicet Bio, Inc. METHODS FOR EXPANDING γδ T-CELL POPULATIONS WITH MULTIVALENT AGENTS AND COMPOSITIONS THEREOF
WO2021176373A1 (en) * 2020-03-03 2021-09-10 Janssen Biotech, Inc. ꝩδ T CELLS AND USES THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
JP7611820B2 (ja) * 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
KR20220004751A (ko) * 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトVγ9Vδ2 T細胞受容体と結合する免疫グロブリン
WO2020159368A1 (en) * 2019-02-01 2020-08-06 Lava Therapeutics B.V. Novel cd40-binding antibodies
WO2021113558A2 (en) * 2019-12-03 2021-06-10 Adicet Bio, Inc. METHODS FOR EXPANDING γδ T-CELL POPULATIONS WITH MULTIVALENT AGENTS AND COMPOSITIONS THEREOF
WO2021176373A1 (en) * 2020-03-03 2021-09-10 Janssen Biotech, Inc. ꝩδ T CELLS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLIN. IMMUNOL., vol. 169, JPN6026030725, 2016, pages 128 - 138, ISSN: 0005913263 *

Also Published As

Publication number Publication date
TW202334233A (zh) 2023-09-01
EP4460521A1 (en) 2024-11-13
WO2023133394A1 (en) 2023-07-13
CN119213028A (zh) 2024-12-27
AU2023205911A1 (en) 2024-07-11
US20250066477A1 (en) 2025-02-27
IL314073A (en) 2024-09-01
KR20240130130A (ko) 2024-08-28
CA3242658A1 (en) 2023-07-13
MX2024008389A (es) 2024-12-06

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾il-2ポリペプチドを含むポリペプチド及びその使用
TWI918596B (zh) Ox40結合多肽及其用途
US20250320295A1 (en) CD8-Binding Polypeptides and Uses Thereof
US20250136681A1 (en) NKp46-Binding Polypeptides and Uses Thereof
KR20230035076A (ko) 변형된 il-2 폴리펩티드를 포함하는 폴리펩티드 및 이의 용도
US20250066477A1 (en) Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
CN114127115A (zh) 结合CLEC12a的多肽及其用途
US20240376198A1 (en) NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
RU2802070C2 (ru) Ох40-связывающие полипептиды и их применение
CN117980335A (zh) Cd8结合多肽及其用途
HK40050757A (en) Ox40-binding polypeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240801

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260721